News
TERN
7.10
+2.31%
0.16
Weekly Report: what happened at TERN last week (1028-1101)?
Weekly Report · 19h ago
Optimistic Outlook for Terns Pharmaceuticals: Potential of TERN-701 Amidst Market Opportunities
TipRanks · 3d ago
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 4d ago
Wingstop upgraded, Estee Lauder downgraded: Wall Street’s top analyst calls
TipRanks · 4d ago
Terns Pharmaceuticals Price Target Announced at $17.00/Share by Oppenheimer
Dow Jones · 4d ago
Oppenheimer Initiates Coverage On Terns Pharma with Outperform Rating, Announces Price Target of $17
Benzinga · 4d ago
Terns Pharmaceuticals initiated with an Outperform at Oppenheimer
TipRanks · 4d ago
Weekly Report: what happened at TERN last week (1021-1025)?
Weekly Report · 10/28 09:16
Terns Pharmaceuticals: Another Potential GLP-1 Entrant
Seeking Alpha · 10/21 16:31
Weekly Report: what happened at TERN last week (1014-1018)?
Weekly Report · 10/21 09:16
Weekly Report: what happened at TERN last week (1007-1011)?
Weekly Report · 10/14 09:19
Institutional investors in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) lost 9.7% last week but have reaped the benefits of longer-term growth
Simply Wall St · 10/11 11:11
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
Barchart · 10/07 15:05
Weekly Report: what happened at TERN last week (0930-1004)?
Weekly Report · 10/07 09:18
TERNS PHARMACEUTICALS INC <TERN.O>: MIZUHO RAISES TARGET PRICE TO $14 FROM $10
Reuters · 09/30 09:36
Weekly Report: what happened at TERN last week (0923-0927)?
Weekly Report · 09/30 09:17
U.S. RESEARCH ROUNDUP-Coca-Cola, Estée Lauder, Quanta Services
Reuters · 09/30 06:04
Terns Pharmaceuticals Currently Down Seven Consecutive Days, on Track for Record Losing Streak -- Data Talk
Dow Jones · 09/27 15:14
Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst
Seeking Alpha · 09/25 14:30
Insiders Snap Up These 2 ‘Strong Buy’ Stocks
TipRanks · 09/24 04:22
More
Webull provides a variety of real-time TERN stock news. You can receive the latest news about Terns Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TERN
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.